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Abstract
Background:  Anaemia is a common complication of chronic kidney disease and prevalence
increases with declining renal function. Renal anaemia has significant implications for the well-being
and quality of life of patients and impacts on morbidity and mortality. Anaemia can be well managed
by therapy with erythropoiesis-stimulating agents (ESAs). Previous clinical trials have shown that
the only human cell-line-derived ESA, epoetin delta, is well tolerated and effective in maintaining
haemoglobin levels in anaemic patients with chronic kidney disease. The half-life of epoetin delta
suggests that administration of this agent is feasible once weekly and once every two weeks. We
report on the design and rationale of a trial to compare once weekly vs. twice weekly, and once
weekly vs. once every two weeks dosing of epoetin delta.
Design and methods: This is a randomized, open-label, multicentre trial. Patients aged 18 years
or above with chronic kidney disease (Stages 3–5) are eligible to enter this trial. Two groups of
patients form the trial population, those naïve to ESA therapy and those previously stable on ESA
therapy. There are two primary objectives of this trial: 1) to demonstrate non-inferiority between
twice weekly and once weekly dosing of epoetin delta in previously naïve patients (assessed by
haemoglobin at Week 24); 2) to demonstrate non-inferiority between once weekly and once
every two weeks dosing in previously stable patients (assessed by average haemoglobin over
Weeks 16–24). Among the secondary analyses will be assessments of haematocrit, number(%) of
patients meeting predefined targets for haemoglobin and haematocrit levels, and comparisons of
average dose. All patients will receive study medication for 24 weeks and dose will be adjusted
according to a predefined algorithm to achieve and maintain haemoglobin ≥ 11 g/dL. All patients
completing this trial are eligible to enter a 2-year follow-up study to enable monitoring of
emergent adverse events, anti-erythropoietin antibody responses, maintenance of efficacy and
changes in diabetic retinopathy status.
Discussion: To our knowledge, this trial is the first to randomize ESA-naïve patients to different
dosing regimens of the same ESA. Data generated will help in guiding the most appropriate dosing
frequency for epoetin delta, particularly in those patients new to epoetin delta therapy.
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Background
Chronic kidney disease (CKD) is a growing problem, par-
ticularly in the Western world [1] and anaemia is a com-
mon complication of CKD, with up to half of all patients
affected [2]. Diabetes is the leading cause of CKD in the
Western world and in diabetic CKD patients anaemia
often develops earlier and more severely than in non-dia-
betic patients with similar renal function [3,4]. As kidney
function declines the prevalence of renal anaemia
increases, with most CKD Stage 5 patients (glomerular fil-
tration rate <15 mL/min/1.73 m2), on or off dialysis,
being anaemic [5]. The primary cause of anaemia in CKD
patients is insufficient synthesis of erythropoietin by the
damaged kidneys. Anaemia is associated with fatigue and
reduced quality of life [6] as well as increased morbidity
and mortality [7-9], often due to cardiovascular complica-
tions [10]. In addition, anaemia in diabetic patients has
been linked with the progression of microvascular com-
plications, including retinopathy [11,12]. Renal anaemia
can be managed by treatment with erythropoiesis-stimu-
lating agents (ESAs), which are effective and well-
tolerated [8].
The original recombinant erythropoietins (epoetin alfa
and epoetin beta) are produced in Chinese hamster ovary
cell lines. In contrast, epoetin delta is produced in a
human cell line, via a process of gene-activation [13].
Clinical trials have demonstrated that epoetin delta is well
tolerated and effective in the management of renal anae-
mia in CKD patients irrespective of dialysis status or dose
frequency [14-17].
In a previous clinical trial epoetin delta administered sub-
cutaneously was shown to be effective in predialysis, peri-
toneal dialysis and haemodialysis patients [14]. In this
trial, epoetin delta administered two- or three-times per
week was effective and well tolerated in patients irrespec-
tive of dialysis status (predialysis, peritoneal dialysis,
haemodialysis). Administration once per week was effec-
tive in maintaining haemoglobin levels in predialysis and
peritoneal dialysis patients [14,17]. Phase I and II studies
of subcutaneous epoetin delta [18] showed that the half-
life was similar to that of epoetin beta, an agent that can
be administered once per week [19,20]. Patients who are
stable on a once weekly dosing regimen with subcutane-
ous epoetin beta can be switched to once every 2 weeks
administration [21]. The combined evidence from clinical
trials indicates that it may be possible to extend dosing
intervals for epoetin delta beyond once per week. We
report on the design and rationale of a trial to assess this
potential, highlighting its unique aspects.
Design and methods
Design and objectives
This is a multicentre, open-label, randomized, parallel-
group study, designed to provide information on
extended intervals of dosing with epoetin delta
(DYNEPO®, Shire plc) in the management of renal anae-
mia. New dosing regimens will be explored for patients
naïve to ESA therapy and patients already stable on ESA
treatment.
Two primary objectives have been set for this trial:
1. To demonstrate non-inferiority between twice-weekly
(BIW) and once-weekly (QW) dosing of epoetin delta in
previously ESA-naïve patients, as assessed by haemo-
globin at Week 24
2. To demonstrate non-inferiority between QW and once
every two weeks (Q2W) dosing in patients previously sta-
ble on an ESA, as assessed by average haemoglobin over
Weeks 16–24.
Several secondary objectives, including a key secondary
objective, have been included in the trial design and these
are detailed below.
Key secondary objective: to demonstrate non-inferiority
of efficacy between QW and Q2W dose schedules in
patients previously stable on an ESA, as measured by aver-
age dose over Weeks 16–24.
Other secondary objectives:
1) To compare efficacy between BIW and QW dose sched-
ules of epoetin delta in previously ESA-naïve patients and
between QW and Q2W dose schedules in patients previ-
ously stable on an ESA, as measured by:
a) the number (%) of patients who achieve haemoglobin
of ≥ 11 g/dL at Weeks 16 and 24 and over Weeks 16–24.
b) haematocrit at Weeks 16 and 24, and over Weeks 16–24.
c) the number (%) of patients achieving the haematocrit
target range of 33–36% at Weeks 16 and 24 and over
Weeks 16–24.
d) the number (%) of patients who achieve both haemo-
globin and haematocrit targets (≥ 11 g/dL and 33–36%
respectively) at Weeks 16 and 24 and over Weeks 16–24.
2) To compare the average dose over Weeks 9–16, 16–24
and 9–24 between BIW and QW dose schedules of epoe-
tin delta in previously ESA-naïve patients and betweenTrials 2007, 8:35 http://www.trialsjournal.com/content/8/1/35
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QW and Q2W dose schedules in patients previously stable
on an ESA.
3) To compare efficacy between BIW and QW dose sched-
ules of epoetin delta in previously ESA-naïve patients as
measured by haemoglobin at Week 16 and over Weeks
16–24.
4) To compare efficacy between QW and Q2W dose
schedules in patients previously stable on an ESA as meas-
ured by haemoglobin at Weeks 16 and 24.
5) To investigate safety of:
a) BIW and QW dose schedules in previously ESA-naïve
patients.
b) QW and Q2W dose schedules in patients previously
stable on an ESA.
6) To investigate efficacy and safety of epoetin delta when
switching administration frequencies.
7) To summarize efficacy and safety in patients with dia-
betes mellitus (DM).
Ethical considerations
This trial will be conducted in agreement with the current
applicable regulations, ICH, EU Directive 2001/20/EC,
principles of the Declaration of Helsinki and approved by
the relevant review board for all participating study cen-
tres. All patients will give written informed consent before
completing any study-related procedures.
Study groups
Patients are grouped by previous exposure to an ESA and
randomized to differing dose schedules. Group 1 is
formed by ESA-naïve patients, Group 2 by patients previ-
ously stable on ESA therapy (Figure 1). Patients in both
groups are stratified by dialysis status to balance expected
adverse event levels. All participants will be ≥ 18 years of
age, with anaemia due to CKD (Stages 3–5; GFR < 59 mL./
min/1.73 m2). The major inclusion and exclusion criteria
are shown in Table 1. It is planned to include 208 patients
in each arm, randomizing 104 to each dosing regimen,
giving a total patient number of 416.
Study treatments
All patients will receive epoetin delta, administered sub-
cutaneously, for a maximum of 24 weeks. Dose is adjusted
to achieve and maintain haemoglobin ≥ 11 g/dL. If hae-
moglobin is ≥ 12 g/dL OR the rate of increase of haemo-
globin is > 2.5 g/dL/4-week period then the dose is
decreased by 25%. If haemoglobin is < 10 g/dL AND the
rate of increase is < 0.7 g/dL/4-week period then the dose
is increased by 50%. Patients in Group 1 will start on 100
IU/kg/week, and patients in Group 2 will start on a weekly
dose of epoetin delta equivalent to the dose of ESA they
were previously receiving to maintain stability.
Patients will receive a maximum dose of 20 000 IU at any
one time. If the dose schedule determines that they
should receive > 20 000 IU they will be withdrawn from
their randomized arm and followed for safety in a non-
responder rescue group, where their dose of epoetin delta
will continue to be adjusted towards a stable dose on a
schedule that allows for doses of ≥ 20 000 IU at any one
time.
Procedures
Enrolment
Patients are participating at sites in Europe and Australasia
and enrolment started on 30th October 2006. As of 18th
October 2007, 158 patients (43 ESA-naïve) have been
enrolled.
Assessments
The study schedule is shown in Table 2; of note is the
assessment of diabetic retinopathy at screening and final
visit or withdrawal. This will allow baseline data to be col-
lected in the diabetic participants, who can be followed
long-term for changes in retinopathy status.
Statistical methods
416 patients will be included in this study (208 naïve and
208 non-naïve). The primary endpoint for this study is
haemoglobin (g/dL) at Week 24 for ESA-naïve patients
and average haemoglobin over Weeks 16–24 for patients
previously stable on an ESA. Based on a similar study [14]
Trial design Figure 1
Trial design.Trials 2007, 8:35 http://www.trialsjournal.com/content/8/1/35
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and assuming the true difference between dose schedules
is zero (using a non-inferiority margin of 0.75 g/dL), 65
patients in each arm are required to complete the trial
without major protocol violations to provide 90% power.
Full criteria for evaluation are shown in Table 3.
ANCOVA analysis will be used for the endpoint of mean
haemoglobin at Week 24 in each dose group for the ESA-
naïve patients (QW and BIW). A 95% confidence interval
(CI) for the difference between QW and BIW in mean hae-
moglobin will be calculated and non-inferiority of QW
compared with BIW will be concluded if the lower limit of
the 95% CI lies above -0.75 g/dL. For the endpoint of aver-
age haemoglobin over Weeks 16–24 in each dose group
for previously stable patients (QW and BIW), repeated
measures ANCOVA analysis will be used. A 95% CI for the
difference between Q2W and QW in mean haemoglobin
will be calculated and non-inferiority of Q2W compared
with QW will be concluded if the lower limit of the 95%
CI lies above -0.75 g/dL. These results will be assessed in
both per-protocol and intent-to-treat populations. All
patients who receive study medication will be included in
the safety analyses.
Follow up
All patients completing this study will be eligible for
entry into a 2-year, open-label extension to enable
monitoring of emergent adverse events, anti-erythropoie-
tin antibody responses, maintenance of efficacy and
changes in retinopathy status among the diabetic subpop-
ulation. All patients completing the study, but not enter-
ing the open-label extension, will be followed up at Week
28 to review adverse events and record any changes.
Discussion
Epoetin delta, the first human cell line-derived ESA has
been shown to be effective and well-tolerated for the man-
agement of anaemia due to CKD, irrespective of dialysis
status [14,15]. This trial, designed to assess extended dos-
ing regimens of epoetin delta is the first, to our knowl-
edge, to randomize ESA-naïve patients to different dosing
regimens of the same ESA. In addition it addresses the
need for a correction phase of sufficient length when com-
mencing ESA therapy. Previous studies have linked anae-
mia with both increased risk of retinopathy, and in
patients with retinopathy, increased risk of progression to
severe retinopathy [11]. Monitoring of retinopathy status
in the diabetic subpopulation of this trial will provide a
patient baseline for assessing the long-term effects of
managing anaemia with epoetin delta therapy on this
complication of diabetes.
Data generated from this trial should help in offering
patients, particularly those new to ESA therapy, flexibility
in dosing intervals with epoetin delta. The 2-year follow
up to this study will enable long term efficacy and safety
data to be collected.
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Table 1: Major selection criteria
Inclusion criteria
￿ Patients aged at least 18 years of age with CKD (KDOQI Stage 3–5) who are able to give written informed consent and are likely to attend all 
study visits
￿ Stable on any dose ≤ 10 000 IU/week of subcutaneous ESA or requiring initiation of ESA treatment
￿ Those currently receiving ESA treatment must have been receiving a stable dose, that was effective in managing haemoglobin levels (≥ 11 g/dL), for 
at least 30 days before randomization in the study
￿ Those requiring initiation of ESA treatment must have haemoglobin levels ≥ 8 g/dL and < 11 g/dL
￿ Transferrin saturation ≥ 20 % and ferritin ≥ 100 ng/mL
Major exclusion criteria
￿ Uncontrolled hypertension
￿ Requiring doses of ESA > 10 000 IU/week
￿ Two or more doses of prescribed ESA treatment missed or withheld by physician order in the 14 days immediately before randomization in the 
study
￿ Thrombocytopenia (platelet count < 75 000/mm3)
￿ Active bleeding disorder (diathesis) (for example, gastro-intestinal or genito-urinary tract bleeding)
￿ Treatment with immunosuppressive drugs (other than corticosteroids for a chronic condition) in the 30 days immediately before randomization 
in the study
￿ Androgen therapy in the 30 days immediately before randomization in the study
￿ Known HIV infection from medical history
￿ Known or suspected intolerance or hypersensitivity to ESA therapy or to any of the excipients of epoetin delta
￿ Known to have antibodies against erythropoietin
￿ Impaired hepatic function (AST, ALT > 3x ULN)Trials 2007, 8:35 http://www.trialsjournal.com/content/8/1/35
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Table 2: Study schedule
Visit Screening Baseline Visit 2* Visit 3* Visit 4* Visit 5* Visit 6* Visit 7* Visit 8*
Final 
visit/
withdra
wal
Follow-
up call
Week Day -14 to -1 0 2 4 6 8 12 16 20 24 28
Informed 
consent
In/exclusion 
criteria
Randomization
Demographics
Medical history
Physical 
examination
Vital signs
On site 
assessment of 
haemoglobin 
level
Biochemistry 
and 
haematology
Assay for anti-
erythropoietin 
antibodies
Echocardiogram
Retinopathy 
testing1
Serum 
pregnancy test
Urinalysis2
Investigational 
product 
dispensed
Adverse events
Prior and 
concomitant 
medication
Drug 
compliance
*A visit window of ± 3 days will be permitted for study visits 2 to follow-up.
1For diabetic patients only.
2For patients with CKD stage 3 or 4 only.
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9 9 9 9 9 9 9 9 9 9
9 9 9 9 9 9 9 9
9 9 9 9 9 9 9 9 9 9
9 9 9 9
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